[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
about
A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathyRepurposed automated handheld counter as a point-of-care tool to identify individuals 'at risk' of serious post-ivermectin encephalopathyEffect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled TrialParasitological, Hematological and Biochemical Characteristics of a Model of Hyper-microfilariaemic Loiasis (Loa loa) in the Baboon (Papio anubis)Current evidence on the use of antifilarial agents in the management of bancroftian filariasisThe Mectizan Donation Program - highlights from 2005.Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported casesLoa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future.Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.A Framework for Decision-Making for Mass Distribution of Mectizan(R) in Areas Endemic for Loa loa.Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.Potential Role for Flubendazole in Limiting Filariasis Transmission: Observations of Microfilarial Sensitivity.Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa
P2860
Q28217814-262F4F9F-6E5B-4EE6-85BD-BAF9E88B3AEEQ28543058-AC796714-B1DA-4946-9E00-DE21DBA7FB4BQ28550715-68734B80-8673-436D-8BA7-D446EBE031F2Q28550781-94D02558-A104-4B7C-B91C-6CD36245F28FQ34479159-12F0358E-3C6E-40D3-8815-CE3893276005Q35103932-6EC971D5-C288-472F-89FA-6D607B029394Q35671648-CD700091-04A1-4617-B4D7-62CD7F161EC0Q36287263-D41A63AA-FF5C-4947-BC73-360BDAB00F67Q39065670-0922A6BD-F2AE-4F13-AD80-CFFFA292861FQ39577854-002CF6C0-A808-49FC-94B9-2566DC2A6FB5Q42092252-45182CF7-E968-4261-80F9-777892E6A7FEQ42102770-D12F2BB1-4316-41DD-87BD-22A5CB3D126BQ42223959-C40000E4-AFB1-4A0F-A9A4-59234B36296FQ44169900-061FBA25-1AEE-4E5D-8387-C9025178A75DQ58723511-EE8C116D-7AFC-486B-BC5E-AADFC396AED0
P2860
[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
@en
type
label
[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
@en
prefLabel
[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
@en
P2093
P1476
[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
@en
P2093
D Schneider
J P Chippaux
M Boussinesq
N Gardon-Wendel
P304
P407
P577
1995-01-01T00:00:00Z